SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study

International Journal of Infectious Diseases

Puneeth Thatikonda¹  Pankaj Chaturvedi¹  Vedang Murthy¹  Navin Khattry¹  Anant Gokarn¹  Nitin Shetty²  Nikhil Patkar²  Sadhana Kannan²  Sudeep Gupta³  Meera Achrekar⁴  Atanu Bhattacharjee⁵  Anjali Rawat⁶  Preeti Chavan⁷  Amar Patil⁷  Amey Oak⁷  Sumeet Mirgh⁸  Prasanth Bhat⁸  Amit Joshi⁸  Ashwini More⁹  Sujeet Kamtalwar⁹  Rajendra Badwe^1,10  Siddhartha Laskar^1,10  Sachin Dhumal^1,11  Suvarna Gore^1,11  Bhakti Trivedi^1,12 

[1] Homi Bhabha National Institute, Mumbai, India;Centre for Cancer Epidemiology, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai, India;;Department of Anaesthesiology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, &Department of Biostatistics, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai, India;Department of Composite Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai, India;Department of Hematopathology, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai, India;Department of Medical Administration, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai, India;;Department of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, &Department of Medicine, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai, India;;Department of Nursing, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, &Department of Radiation Oncology, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai, India;Department of Radiodiagnosis, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Tata Memorial Centre, Navi Mumbai, India;

关键词: SARS-CoV-2;    Reinfection;    Vaccine breakthrough infection;    ChAdOx1 nCoV-19 vaccine;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: There are sparse longitudinal data on SARS-CoV-2 infection after previous infection and after partial or full vaccination. Methods: This study of a cohort of healthcare workers used Kaplan-Meier analysis with appropriate definition of events and censoring and used Cox models to assess outcomes, with data cut-off on June 18, 2021. Results: A total of 1806 individuals with median age of 32 (18-64) years, 1483 (82.1%) with at least one vaccine dose, 1085 (60.1%) with 2 vaccine doses, 408 (22.6%) with at least one episode of SARS-CoV-2 infection, and 6 (1.47%) with 2 episodes of infection were included in the analysis. At median follow-up of 38.4 weeks after first SARS-CoV-2 infection (n=408), the 52-week probability of reinfection was 2.2% (95% CI, 1.0-4.91%); and at median follow-up of 13.3 weeks after second dose, the 16-week probability of breakthrough infection was 5.6% (95% CI, 4.33-7.23%), which was significantly higher among those without previous SARS-CoV-2 infection versus with previous infection (6.4% vs 1.8%, p=0.016, adjusted Cox HR=3.49, 95% CI, 1.09-11.20, p=0.036) and females versus males (7.9% vs 3.8%, p=0.007, adjusted Cox HR=2.06, 95% CI 1.19-3.56, p=0.01). Conclusions: There was low probability of reinfection after previous SARS-CoV-2 infection and higher vaccine breakthrough infections among females and those without previous infection.

【 授权许可】

Unknown